Novavax (NVAX) Reports Positive Phase 1 Data for COVID-19 Vaccine Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate
August 4, 2020 4:06 PM EDTPhase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax COVID-19 vaccine across two dose levels (5 and 25 µg) in 131 healthy adults ages 18-59 yearsNVX-CoV2373 was generally well-tolerated and had a reassuring safety profileThe vaccine induced neutralization titers in 100% of participants Both 5 µg and 25 µg adjuvanted doses generated peak geometric mean titer (GMT) greater than 1:3,300 Matrix-M adjuvant induced robust polyfunctional CD4+ T cell responsesConference call to be held on Tuesday,... More
